Skip to content

Medical-device intelligence

PZM: Next Generation Sequencing Based Tumor Profiling Test

FDA product code PZM: Next Generation Sequencing Based Tumor Profiling Test. View classification details, related manufacturers, 510(k) clearances, and recall records.

FDA classification ↗

Classification details

Product code
PZM
FDA device name
Next Generation Sequencing Based Tumor Profiling Test
Device class
2
Regulation number
866.6080
Medical specialty
Pathology
Review panel
PA

FDA definition

A next-generation sequencing based tumor profiling test is a qualitative in vitro diagnostic test intended to detect mutations in a broad panel of targeted genes that are somatically altered in malignant neoplasms from tumor specimens obtained from patients diagnosed with malignant solid neoplasms using targeted next-generation sequencing.
Explore pathology records →
A product code groups records by FDA classification. It does not establish identical intended uses, commercial availability, or comparative device safety.

Record activity in this scope

7 clearance records and 0 recall records in the covered releases, across 7 source company names and 1 product codes. Dated history runs from Nov 9, 2019 to May 12, 2026.

Monthly counts through October 2026
Month510(k) decisionsRecall initiations
October 202500
November 202500
December 202500
January 202600
February 202600
March 202600
April 202600
May 202610
June 202600
July 202600
August 202600
September 202600
October 202600

Product codes represented

Code and FDA device nameClearancesRecalls
PZM · Next Generation Sequencing Based Tumor Profiling Test70

All-history totals use the covered releases; monthly counts stop at the last calendar month covered by both sources. Clearances use decision dates; recalls use initiation dates. 0 records lack the required date and are excluded from monthly counts. These are records, not product launches, market share, incidence rates, or comparative safety. Feed filters below do not change this overview.

Clearances and recall records

7 matching records
Device / recordCompany in FDA recordSourceSource date
CellDx-TissueK260235 · PZMDatar Cancer Genetics Private Limited510(k)May 12, 2026FDA decision date
xR IVDK241868 · PZMTempus AI, Inc.510(k)Sep 19, 2025FDA decision date
GENESEEQPRIME NGS Tumor Profiling Assay (FFPE) (GS6005)K250003 · PZMGeneseeq Technology, Inc.510(k)Aug 29, 2025FDA decision date
ACTOnco, ACTOnco IVDK210017 · PZMAct Genomics510(k)Dec 23, 2022FDA decision date
NYU Langone Genome PACT (Genome Profiling of Actionable Cancer Targets)K202304 · PZMNyu Langone Medical Center510(k)Jul 14, 2021FDA decision date
PGDx elio tissue completeK192063 · PZMPersonal Genome Diagnostics510(k)Apr 24, 2020FDA decision date
Omics CoreK190661 · PZMNanthealth, Inc.510(k)Nov 9, 2019FDA decision date

Manufacturers in these records

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 21, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 21, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 21, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗